Skip to main content
NCBI home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(2):264–275. doi: 10.1016/j.nurx.2006.01.011

Pediatric multiple sclerosis

Dorothée Chabas 1,✉, Ari J Green 1, Emmanuelle Waubant 1
PMCID: PMC3593440  PMID: 16554264

Summary

Multiple sclerosis (MS) occurs at all ages of the pédiatric population. Childhood MS may represent up to 10% of all MS cases. Establishing the diagnosis of MS in a child is complicated by the limited diagnostic criteria and the possibility of significant clinical and magnetic resonance imaging (MRI) overlap with acute disseminated encephalomyelitis and other pediatric diseases. Although the clinical profile of MS appears similar to that seen in adults, several features may differ and specific issues arise in children. Sex ratios are different between young children with MS and adolescents— implicating a role for sex hormones in disease pathogenesis and/or modification of disease expression. Younger patients with MS are more likely to have seizures, brainstem, and cerebellar symptoms than adults. Children with MS may have fewer T2 hyperintense areas on MRI scans, therefore not meeting MRI criteria established for adults. It is possible that the pediatric MS course is more indolent than in adult patients but the disease may lead to significant disability at a younger age, e.g., while patients are students, young professionals, or want to start a family. There has been no controlled clinical trial in children with disease modifying therapies approved for adult MS due to the limited number of patients under the age of 18 years compared with the adult contingent. As a result, children are receiving adult therapies in an arbitrary manner and our understanding of pediatric treatment effect and tolerability is limited. Available data on tolerability of approved drugs for adults is reviewed.

Key Words: Multiple sclerosis, acute disseminated encephalomyelitis, pediatric, treatments, review

References

  • 1.Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–952. doi: 10.1056/NEJM200009283431307. [DOI] [PubMed] [Google Scholar]
  • 2.Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907–911. doi: 10.1212/WNL.46.4.907. [DOI] [PubMed] [Google Scholar]
  • 3.Medaer R. Does the history of multiple sclerosis go back as far as the 14th century? Acta Neurol Scand. 1979;60:189–192. doi: 10.1111/j.1600-0404.1979.tb02968.x. [DOI] [PubMed] [Google Scholar]
  • 4.Shaw CM, Alvord EC. Multiple sclerosis beginning in infancy. J Child Neurol. 1987;2:252–256. doi: 10.1177/088307388700200403. [DOI] [PubMed] [Google Scholar]
  • 5.Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand. 1992;86:280–284. doi: 10.1111/j.1600-0404.1992.tb05086.x. [DOI] [PubMed] [Google Scholar]
  • 6.Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, Confavreux C, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr. 2004;144:246–252. doi: 10.1016/j.jpeds.2003.10.056. [DOI] [PubMed] [Google Scholar]
  • 7.Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  • 8.McDonald WI, Compston A, Edan G, Goodkin D, Haltung HP, Lublin F, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127. doi: 10.1002/ana.1032. [DOI] [PubMed] [Google Scholar]
  • 9.Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain. 1990;113:1477–1489. doi: 10.1093/brain/113.5.1477. [DOI] [PubMed] [Google Scholar]
  • 10.Hahn CD, Shroff MM, Blaser SI, Banwell BL. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology. 2004;62:806–808. doi: 10.1212/01.WNL.0000113723.36715.A6. [DOI] [PubMed] [Google Scholar]
  • 11.Hauser SL, Bresnan MJ, Reinherz MJ, Weiner HL. Childhood multiple sclerosis: clinical features and demonstration of changes in T cell subsets with disease activity. Ann Neurol. 1982;11s:463–468. doi: 10.1002/ana.410110505. [DOI] [PubMed] [Google Scholar]
  • 12.Duquette P., Murray TJ, Pleines J, Ebers GC, Sadovnick D, Weldon P, et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr. 1987;111:359–363. doi: 10.1016/S0022-3476(87)80454-7. [DOI] [PubMed] [Google Scholar]
  • 13.Bauer HJ, Hanefeld F, Christen HJ. Multiple sclerosis in early childhood. Lancet. 1990;336:1190–1190. doi: 10.1016/0140-6736(90)92802-O. [DOI] [PubMed] [Google Scholar]
  • 14.Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 1991;13:410–416. doi: 10.1016/S0387-7604(12)80038-6. [DOI] [PubMed] [Google Scholar]
  • 15.Perniola T, Russo MG, Margari L, Buttiglione M, Simone IL. Multiple sclerosis in childhood: longitudinal study in 14 cases. Acta Neurol (Napoli) 1991;13:236–248. [PubMed] [Google Scholar]
  • 16.Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997;3:43–46. doi: 10.1177/135245859700300105. [DOI] [PubMed] [Google Scholar]
  • 17.Pinhas-Hamiel O, Barak Y, Siev-Ner I, Achiron A. Juvenile multiple sclerosis: clinical features and prognostic characteristics. J Pediatr. 1998;132:735–737. doi: 10.1016/S0022-3476(98)70371-3. [DOI] [PubMed] [Google Scholar]
  • 18.Ruggieri M., Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age. Neurology. 1999;53:478–484. doi: 10.1212/WNL.53.3.478. [DOI] [PubMed] [Google Scholar]
  • 19.Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000;123:2407–2422. doi: 10.1093/brain/123.12.2407. [DOI] [PubMed] [Google Scholar]
  • 20.Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM. Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis: multiple sclerosis in children under 10 years of age. Neurol Sci. 2004;25(Suppl 4):S326–S335. doi: 10.1007/s10072-004-0335-z. [DOI] [PubMed] [Google Scholar]
  • 21.Ghezzi A. Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. Expert Rev Neurother. 2005;5:403–411. doi: 10.1586/14737175.5.3.403. [DOI] [PubMed] [Google Scholar]
  • 22.Rose AS, Ellison GW, Myers LW, Tourtelotte WW. Criteria for the clinical diagnosis of multiple sclerosis. Neurology. 1976;26:20–22. doi: 10.1212/WNL.26.6_Part_2.20. [DOI] [PubMed] [Google Scholar]
  • 23.Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease? Neurol Sci. 2004;25(Suppl 4):S323–S325. doi: 10.1007/s10072-004-0334-0. [DOI] [PubMed] [Google Scholar]
  • 24.Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol Sci. 2004;25:S336–S339. doi: 10.1007/s10072-004-0336-y. [DOI] [PubMed] [Google Scholar]
  • 25.Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–717. doi: 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 26.Banwell B, Kennedy J, Krupp L, Bar-Or A, Tenembaum S, Belman A, et al. Clinical and demographic features of pediatric MS: preliminary data from a multinational collaborative study. Neurology. 2004;62:A230–A230. [Google Scholar]
  • 27.Cole GF., Auchterlonie LA, Best PV. Very early onset multiple sclerosis. Dev Med Child Neurol. 2005;37:667–672. doi: 10.1111/j.1469-8749.1995.tb15011.x. [DOI] [PubMed] [Google Scholar]
  • 28.Banwell BL. Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005;64:891–894. doi: 10.1212/01.WNL.0000152896.35341.51. [DOI] [PubMed] [Google Scholar]
  • 29.MacAllister WS, Belman AL, Milazzo M, Weisbrot DM, Christodoulou C, Scherl WF, et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005;64:1422–1425. doi: 10.1212/01.WNL.0000158474.24191.BC. [DOI] [PubMed] [Google Scholar]
  • 30.Hahn CD., Miles BS, Macgregor DL, Blaser SI, Banwell BL, Hetherington CR. Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr Neurol. 2003;29:117–123. doi: 10.1016/S0887-8994(03)00143-7. [DOI] [PubMed] [Google Scholar]
  • 31.Baoxun ZDL, Weiming H, Xiugun L, Shihe L, Yinchang Y, Sinmei J, et al. MS in China: a clinical study of 256 cases. In: Kuroiwa LKY, et al., editors. Multiple Sclerosis East and West. Fukuoka, Japan: Kyushu University Press; 1982. pp. 71–81. [Google Scholar]
  • 32.Higa H, Toyonaga K, Nishihara T, Sakugawa H, Ikuta F. MS in Okinawa. In: Kuroiwa LKY, editor. Multiple Sclerosis East and West. Fukuoka, Japan: Kyushu University Press; 1982. pp. 49–56. [Google Scholar]
  • 33.Hung TP. MS in Taiwan: a reappraisal. In: Kuroiwa LKY, editor. Multiple Sclerosis East and West. Fukuoka, Japan: Kyushu University Press; 1982. pp. 83–96. [Google Scholar]
  • 34.Kim SW, Kim SK. Multiple sclerosis in Busan Korea: clinical features and prevalence. In: Kuroiwa LKY, editor. Multiple Sclerosis East and West. Fukuoka, Japan: Kyushu University Press; 1982. pp. 57–80. [Google Scholar]
  • 35.Shiraishi K, Higuchi Yozawa K, Hao Q, Saida T. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan. Brain Dev. 2005;27:224–227. doi: 10.1016/j.braindev.2004.06.005. [DOI] [PubMed] [Google Scholar]
  • 36.Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-bom children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry. 1990;53:906–911. doi: 10.1136/jnnp.53.10.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zelnik N., Gale AD, Shelbume SA. Multiple sclerosis in black children. J Child Neurol. 1991;6:53–57. doi: 10.1177/088307389100600112. [DOI] [PubMed] [Google Scholar]
  • 38.Mikaeloff Y, Actamsbaum C, Husson B, Vallee L, Ponsot G, Confavreux C, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004;127:1942–1947. doi: 10.1093/brain/awh218. [DOI] [PubMed] [Google Scholar]
  • 39.Triulzi F, Scotti G. Differential diagnosis of multiple sclerosis: contribution of magnetic resonance techniques. J Neurol Neurosurg Psychiatry. 1998;64(Suppl 1):S6–S14. [PubMed] [Google Scholar]
  • 40.Hynson JL., Komberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001;56:1308–1312. doi: 10.1212/WNL.56.10.1308. [DOI] [PubMed] [Google Scholar]
  • 41.Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004;63:1966–1967. doi: 10.1212/01.WNL.0000144352.67102.BC. [DOI] [PubMed] [Google Scholar]
  • 42.Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA. 2004;291:1875–1879. doi: 10.1001/jama.291.15.1875. [DOI] [PubMed] [Google Scholar]
  • 43.Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci. 1998;160:16–25. doi: 10.1016/S0022-510X(98)00116-6. [DOI] [PubMed] [Google Scholar]
  • 44.Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435–442. doi: 10.1007/s004150070172. [DOI] [PubMed] [Google Scholar]
  • 45.Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178. doi: 10.1212/WNL.58.2.169. [DOI] [PubMed] [Google Scholar]
  • 46.Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol. 1995;113:136–137. doi: 10.1001/archopht.1995.01100020014004. [DOI] [PubMed] [Google Scholar]
  • 47.Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology. 1998;50:1833–1836. doi: 10.1212/WNL.50.6.1833. [DOI] [PubMed] [Google Scholar]
  • 48.Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler. 2000;6:267–273. doi: 10.1177/135245850000600408. [DOI] [PubMed] [Google Scholar]
  • 49.Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878–886. doi: 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 50.Takahashi I, Sawaishi Y, Takeda O, Enoki M, Takada G. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol. 1997;17:83–87. doi: 10.1016/S0887-8994(97)80673-X. [DOI] [PubMed] [Google Scholar]
  • 51.Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol. 1998;21:258–261. [PubMed] [Google Scholar]
  • 52.Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol. 1999;21:583–586. doi: 10.1016/S0887-8994(99)00042-9. [DOI] [PubMed] [Google Scholar]
  • 53.Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev. 1999;21:279–282. doi: 10.1016/S0387-7604(99)00011-X. [DOI] [PubMed] [Google Scholar]
  • 54.Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci. 1999;165:56–61. doi: 10.1016/S0022-510X(99)00072-6. [DOI] [PubMed] [Google Scholar]
  • 55.Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54:1370–1372. doi: 10.1212/WNL.54.6.1370. [DOI] [PubMed] [Google Scholar]
  • 56.Noseworthy JH, O’Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514–1522. doi: 10.1212/WNL.56.11.1514. [DOI] [PubMed] [Google Scholar]
  • 57.Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63:2028–2033. doi: 10.1212/01.WNL.0000145798.61383.39. [DOI] [PubMed] [Google Scholar]
  • 58.The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661. doi: 10.1212/WNL.43.4.655. [DOI] [PubMed] [Google Scholar]
  • 59.Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276. doi: 10.1212/WNL.45.7.1268. [DOI] [PubMed] [Google Scholar]
  • 60.Jacobs LD, Cookfair DL, Rudick RA, Hemdon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996;39:285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  • 61.PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504. doi: 10.1016/S0140-6736(98)03334-0. [DOI] [PubMed] [Google Scholar]
  • 62.Comi G, Filippi M, Wolinsky JS. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49:290–297. doi: 10.1002/ana.64. [DOI] [PubMed] [Google Scholar]
  • 63.Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904. doi: 10.1056/NEJM200009283431301. [DOI] [PubMed] [Google Scholar]
  • 64.Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582. doi: 10.1016/S0140-6736(00)04725-5. [DOI] [PubMed] [Google Scholar]
  • 65.PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628–1636. doi: 10.1212/WNL.56.12.1628. [DOI] [PubMed] [Google Scholar]
  • 66.Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018–2025. doi: 10.1016/S0140-6736(02)12023-X. [DOI] [PubMed] [Google Scholar]
  • 67.Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;28:362–368. doi: 10.1056/NEJMoa051586. [DOI] [PubMed] [Google Scholar]
  • 68.Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;28:369–374. doi: 10.1056/NEJMoa051782. [DOI] [PubMed] [Google Scholar]
  • 69.Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–381. doi: 10.1056/NEJMoa051847. [DOI] [PubMed] [Google Scholar]
  • 70.Miller DH, Khan OA, Sheremata WA, Blimhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23. doi: 10.1056/NEJMoa020696. [DOI] [PubMed] [Google Scholar]
  • 71.Polman C, O’Connor P, Havrdova E, et al. Clinical results from AFFIRM: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing remitting multiples sclerosis (MS) Neurology. 2005;64(Suppl 1):A146–A146. [Google Scholar]
  • 72.O’Connor P, Havrdova E, Hutchinson M, et al. Safety, tolerability and immunogenicity of natalizumab: results from the AFFIRM trial. Neurology. 2005;64(Suppl 1):A146–A146. [Google Scholar]
  • 73.Miller D, O’Connor P, Havrdova E, et al. The efficacy of natalizumab on magnetic resonance imaging measures in patients with relapsing remitting multiple sclerosis: results from the AFFIRM trial. Neurology. 2005;64(Suppl 1):A146–A146. [Google Scholar]
  • 74.Rudick R, Stuart W, Calabresi P, et al. SENTINEL: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab, when added to intramuscular interferon beta-1a, in patients with relapsing multiple sclerosis. One year clinical and MRI results. Neurology. 2005;64(Suppl 1):A276–A276. [Google Scholar]
  • 75.Calabresi P, Stuart W, Confavreux C, et al. Safety and tolerability of natalizumab: results from the SENTINEL study. Neurology. 2005;64(Suppl 1):A277–A277. [Google Scholar]
  • 76.Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001;57:1969–1975. doi: 10.1212/WNL.57.11.1969. [DOI] [PubMed] [Google Scholar]
  • 77.Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 2001;56:1505–1513. doi: 10.1212/WNL.56.11.1505. [DOI] [PubMed] [Google Scholar]
  • 78.Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56:1496–1504. doi: 10.1212/WNL.56.11.1496. [DOI] [PubMed] [Google Scholar]
  • 79.Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679–687. doi: 10.1212/WNL.59.5.679. [DOI] [PubMed] [Google Scholar]
  • 80.Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60:44–51. doi: 10.1212/WNL.60.1.44. [DOI] [PubMed] [Google Scholar]
  • 81.Kita M, Cohen J, Fox B, et al. A phase II trial of mitoxantrone in patients with primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2004;62(Suppl 5):A99–A99. [Google Scholar]
  • 82.Wolinsky J, Pardo L, Stark Y, et al. Effect of glatiramer acetate on primary progressive multiple sclerosis: initial analysis of the completed PROMiSe trial. Neurology. 2004;62(Suppl 5):A97–A97. [Google Scholar]
  • 83.Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004;364:1149–1156. doi: 10.1016/S0140-6736(04)17101-8. [DOI] [PubMed] [Google Scholar]
  • 84.Tenmbaum S, Banwell B, Boiko A, et al. Treatment of childhood and adolescent multiple sclerosis with interferon beta-1b. Neurology. 2005;64(Suppl 1):A384–A384. [Google Scholar]
  • 85.Actams AB, Tyor WR, Holden KR. Interferon beta-1b and childhood multiple sclerosis. Pediatr Neurol. 1999;21:481–483. doi: 10.1016/S0887-8994(99)00007-7. [DOI] [PubMed] [Google Scholar]
  • 86.Schilling S, Haertel C, Spemer J. Follow-up of interferon beta-1b treatment in patients with secondary progressive multiple sclerosis. Neuropediatrics. 2002;33:A31–A31. [Google Scholar]
  • 87.Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001;32:211–213. doi: 10.1055/s-2001-17370. [DOI] [PubMed] [Google Scholar]
  • 88.Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001;139:443–446. doi: 10.1067/mpd.2001.117004. [DOI] [PubMed] [Google Scholar]
  • 89.Ghezzi A, Ruggieri M, Trojano M, Filippi M. Italian studies on early-onset multiple sclerosis: the present and the future. Neurol Sci. 2004;25(Suppl 4):S346–S349. doi: 10.1007/s10072-004-0346-9. [DOI] [PubMed] [Google Scholar]
  • 90.Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64:888–890. doi: 10.1212/01.WNL.0000153570.33845.6A. [DOI] [PubMed] [Google Scholar]
  • 91.Tenembaum S, Segura M. Interferon beta-1a is effective and well tolerated in paediatric patients: results of a 6-year study.Multiple Scler (in press).
  • 92.Etheridge LJ, Beverley DW, Feme C, McManus E. The use of interferon beta in relapsing-remitting multiple sclerosis. Arch Dis Child. 2004;89:789–791. doi: 10.1136/adc.2003.040881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Komek B, Bernert G, Balassy C, Geldner J, Rayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003;34:120–126. doi: 10.1055/s-2003-41274. [DOI] [PubMed] [Google Scholar]
  • 94.Krupp LB, Macallister WS. Treatment of pediatric multiple slerosis. Curr Treat Options Neurol. 2005;7:191–199. doi: 10.1007/s11940-005-0012-4. [DOI] [PubMed] [Google Scholar]
  • 95.Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology. 2002;59:802–808. doi: 10.1212/WNL.59.6.802. [DOI] [PubMed] [Google Scholar]
  • 96.Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group: every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet. 2002;359:1453–1460. doi: 10.1016/S0140-6736(02)08430-1. [DOI] [PubMed] [Google Scholar]
  • 97.Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, et al. EVIDENCE Study Group. Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59:1496–1506. doi: 10.1212/01.WNL.0000034080.43681.DA. [DOI] [PubMed] [Google Scholar]
  • 98.PRISMS Study Group. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005;65:48–55. doi: 10.1212/01.wnl.0000171748.48188.5b. [DOI] [PubMed] [Google Scholar]
  • 99.Banwell B. Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother. 2005;5:391–401. doi: 10.1586/14737175.5.3.391. [DOI] [PubMed] [Google Scholar]
  • 100.Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 1997;349:589–593. doi: 10.1016/S0140-6736(96)09377-4. [DOI] [PubMed] [Google Scholar]
  • 101.Achiron A, Gabbay U, Gilad R., Hassin-Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology. 1998;50:398–402. doi: 10.1212/WNL.50.2.398. [DOI] [PubMed] [Google Scholar]
  • 102.Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998;50:1273–1281. doi: 10.1212/WNL.50.5.1273. [DOI] [PubMed] [Google Scholar]
  • 103.Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology. 1991;41:20–25. doi: 10.1212/WNL.41.1.20. [DOI] [PubMed] [Google Scholar]
  • 104.Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991;338:1051–1055. doi: 10.1016/0140-6736(91)91909-E. [DOI] [PubMed] [Google Scholar]
  • 105.Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet. 1997;350:261–261. doi: 10.1016/S0140-6736(97)24030-4. [DOI] [PubMed] [Google Scholar]
  • 106.Cavazzuti M, Merelli E, Tassone G, Mavilla L. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment: a retrospective study. Eur Neurol. 1997;38:284–290. doi: 10.1159/000113395. [DOI] [PubMed] [Google Scholar]
  • 107.Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308:173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  • 108.The Canadian Cooperative Multiple Sclerosis Study Group The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337:441–446. [PubMed] [Google Scholar]
  • 109.Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993;43:910–918. doi: 10.1212/WNL.43.5.910. [DOI] [PubMed] [Google Scholar]
  • 110.Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol. 1999;99:142–149. doi: 10.1016/S0165-5728(99)00039-9. [DOI] [PubMed] [Google Scholar]
  • 111.Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler. 2005;11:573–582. doi: 10.1191/1352458505ms1210oa. [DOI] [PubMed] [Google Scholar]
  • 112.Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37:30–40. doi: 10.1002/ana.410370108. [DOI] [PubMed] [Google Scholar]
  • 113.Goodkin DE, Rudick RA, VanderBrug Medendoip S, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology. 1996;47:1153–1157. doi: 10.1212/WNL.47.5.1153. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES